JAMA cardiology | 2021

Long-term Clinical and Echocardiographic Outcomes in Young and Middle-aged Adults Undergoing the Ross Procedure.

 
 
 
 
 
 
 
 
 
 
 
 

Abstract


Importance\nThere is no ideal valve substitute for young adults requiring aortic valve replacement. Multicenter data supporting use of the Ross procedure with respect to long-term postoperative valve-related mortality and reintervention, as well as function of the autograft and pulmonary homograft, are needed.\n\n\nObjective\nTo determine the long-term clinical and echocardiographic outcomes in young and middle-aged patients undergoing the Ross procedure.\n\n\nDesign, Setting, and Participants\nA retrospective multicenter international cohort study with a median follow-up period of 9.2 years was conducted in 5 experienced centers regularly performing the Ross procedure. Consecutive patients aged 18 to 65 years were included by each center between 1991 and 2018.\n\n\nMain Outcomes and Measures\nSurvival and autograft-related and homograft-related reintervention. Serial echocardiographic measurements of valve function were analyzed using mixed-effects modeling.\n\n\nResults\nDuring the study period, 1431 patients (74.3% men; n\u2009=\u20091063) were operated on at a median age of 48.5 years (mean [SD], 47.7 [9.5]; range, 18.1-65; interquartile range, 42.7-54.0). Implantation techniques were root inclusion in 355 (24.9%), root replacement in 485 (34.0%), and subcoronary implantation in 587 (41.1%). Right ventricular outflow tract reconstruction was performed with homografts in 98.6% (n\u2009=\u20091189) and bioprostheses in 1.4% (n\u2009=\u200917). Ten patients (0.7%) died before discharge. Median follow-up was 9.2 years (13\u202f015 total patient-years). Survival after 10 and 15 years was 95.1% (95% CI, 93.8%-96.5%) and 88.5% (95% CI, 85.9%-91.1%), respectively. Freedom from autograft and homograft reintervention after 15 years was 92.0% and 97.2%, respectively. Late events were autograft endocarditis in 14 patients (0.11% per patient-year), homograft endocarditis in 11 patients (0.08% per patient-year), and stroke in 37 patients (0.3% per patient-year).\n\n\nConclusions and Relevance\nGiven its excellent short-term and long-term outcome in young and middle-aged adults in this study, the Ross procedure should be considered in young and middle-aged adults who require aortic valve replacement. Patients should be referred to an experienced center with a program dedicated to the Ross procedure.

Volume None
Pages None
DOI 10.1001/jamacardio.2020.7434
Language English
Journal JAMA cardiology

Full Text